The Citrus Flavanone Naringenin Protects Myocardial Cells against Age-Associated Damage

Oxidative Medicine and Cellular Longevity

Volumn 2017, Issue , 2017, Pages

  Da Pozzo, Eleonora ^a   Costa, Barbara ^a   Cavallini, Chiara ^a   Testai, Lara ^a   Martelli, Alma ^a   Calderone, Vincenzo ^a   Martini, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; ORGANIC COMPOUNDS;

ANTIOXIDANT EFFECT; BENEFICIAL EFFECTS; CELL CYCLE REGULATORS; CELLULAR SENESCENCE; CITRUS FLAVANONES; METABOLIC ACTIVITY; PROTECTIVE PROPERTIES; SIGNALING FUNCTIONS;

FLAVONOIDS;

BETA GALACTOSIDASE; ESTRADIOL; ESTROGEN; NARINGENIN; REACTIVE OXYGEN METABOLITE; ANTIOXIDANT; FLAVANONE DERIVATIVE;

AGING; ANIMAL CELL; ARTICLE; CALCIUM HOMEOSTASIS; CARDIAC MUSCLE CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CITRUS; COLORIMETRY; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; EFFECTIVE CONCENTRATION; ESTROGEN SYNTHESIS; FLUOROMETRY; GENE EXPRESSION; H9C2 CELL LINE; HEART PROTECTION; MITOCHONDRIAL RESPIRATION; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; SENESCENCE; STAINING; ANIMAL; CELL AGING; CHEMISTRY; DRUG EFFECTS; METABOLISM; OXIDATIVE STRESS;

AGING; CELLS; SIMULATION;

AGING; ANIMALS; ANTIOXIDANTS; CELL AGING; CITRUS; FLAVANONES; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES;

EID: 85016547840     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2017/9536148     Document Type: Article

References (74)

1. N. Rani, S. Bharti, B. Krishnamurthy et al., "Pharmacological properties and therapeutic potential of naringenin: a citrus flavonoid of pharmaceutical promise," Current Pharmaceutical Design, vol. 22, no. 28, pp. 4341-4359, 2016.
2. M. A. Alam, N. Subhan, M. M. Rahman, S. J. Uddin, H. M. Reza, and S. D. Sarker, "Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action," Advances in Nutrition, vol. 5, no. 4, pp. 404-417, 2014.
3. 2+ overload in rat ventricular myocytes," American Journal of Physiology-Heart and Circulatory Physiology, vol. 293, no. 1, pp. H307-H313, 2007.
4. L. Testai, S. Rapposelli, A. Martelli, M. C. Breschi, and V. Calderone, "Mitochondrial potassium channels as pharmacological target for cardioprotective drugs," Medicinal Research Reviews, vol. 35, no. 3, pp. 520-553, 2015.
5. G. G. J. M. Kuiper, B. Carlsson, K. Grandien et al., "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β," Endocrinology, vol. 138, no. 3, pp. 863-870, 1997.
6. G. G. Kuiper, J. G. Lemmen, B. Carlsson et al., "Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta," Endocrinology, vol. 139, no. 10, pp. 4252-4263, 1998.
7. M. F. Ruh, T. Zacharewski, K. Connor, J. Howell, I. Chen, and S. Safe, "Naringenin: a weakly estrogenic bioflavonoid that exhibits antiestrogenic activity," Biochemical Pharmacology, vol. 50, no. 9, pp. 1485-1493, 1995.
8. P. Totta, F. Acconcia, S. Leone, I. Cardillo, and M. Marino, "Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor α and β signalling," IUBMB Life, vol. 56, no. 8, pp. 491-499, 2004.
9. D. Guo, J. Wang, X. Wang et al., "Double directional adjusting estrogenic effect of naringin from Rhizoma drynariae (Gusuibu)," Journal of Ethnopharmacology, vol. 138, no. 2, pp. 451-457, 2011.
10. G. Swarnkar, K. Sharan, J. A. Siddiqui et al., "A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts," British Journal of Pharmacology, vol. 165, no. 5, pp. 1526-1542, 2012.
11. E. E. Mulvihill, A. C. Burke, and M.W. Huff, "Citrus flavonoids as regulators of lipoprotein metabolism and atherosclerosis," Annual Review of Nutrition, vol. 36, pp. 275-299, 2016.
12. M. Rajadurai and P. Stanely Mainzen Prince, "Preventive effect of naringin on lipid peroxides and antioxidants in isoproterenol-induced cardiotoxicity in Wistar rats: biochemical and histopathological evidences," Toxicology, vol. 228, no. 2-3, pp. 259-268, 2006.
13. M. Rajadurai and P. S. M. Prince, "Preventive effect of naringin on cardiac mitochondrial enzymes during isoproterenol-induced myocardial infarction in rats: A Transmission Electron Microscopic Study," Journal of Biochemical and Molecular Toxicology, vol. 21, no. 6, pp. 354-361, 2007.
14. L. Testai, A. Martelli, A. Marino et al., "The activation of mitochondrial BK potassium channels contributes to the protective effects of naringenin against myocardial ischemia/reperfusion injury," Biochemical Pharmacology, vol. 85, no. 11, pp. 1634-1643, 2013.
15. G. Mojžišová, L. Mirossay, D. Kučerová, J. Kyselovič, A. Miroššay, and J. Mojžiš, "Protective effect of selected flavonoids on in vitro daunorubicin-induced cardiotoxicity," Phytotherapy Research, vol. 20, no. 2, pp. 110-114, 2006.
16. S. S. Shiromwar and V. R. Chidrawar, "Combined effects of p-coumaric acid and naringenin against doxorubicin-induced cardiotoxicity in rats," Pharmacognosy Research, vol. 3, no. 3, pp. 214-219, 2011.
17. T. K. Reddy, P. Seshadri, K. K. R. Reddy, G. C. Jagetia, and C. D. Reddy, "Effect of Terminalia arjuna extract on adriamycininduced DNA damage," Phytotherapy Research, vol. 22, no. 9, pp. 1188-1194, 2008.
18. M. Miler, J. Živanović, V. Ajdžanović et al., "Citrus flavanones naringenin and hesperetin improve antioxidant status and membrane lipid compositions in the liver of old-aged Wistar rats," Experimental Gerontology, vol. 84, pp. 49-60, 2016.
19. R. Dong, X. Xu, G. Li et al., "Bradykinin inhibits oxidative stress-induced cardiomyocytes senescence via regulating redox state," PLoS ONE, vol. 8, no. 10, Article ID e77034, 2013.
20. D.-F. Dai, Y. A. Chiao, D. J. Marcinek, H. H. Szeto, and P. S. Rabinovitch, "Mitochondrial oxidative stress in aging and healthspan," Longevity & Healthspan, vol. 3, no. 1, article 6, 2014.
21. S. Pepe, "Mitochondrial function in ischaemia and reperfusion of the ageing heart," Clinical and Experimental Pharmacology and Physiology, vol. 27, no. 9, pp. 745-750, 2000.
22. L. Gouva and A. Tsatsoulis, "The role of estrogens in cardiovascular disease in the aftermath of clinical trials," HORMONES, vol. 3, no. 3, pp. 171-183, 2004.
23. J. Hescheler, R. Meyer, S. Plant, D. Krautwurst, W. Rosenthal, and G. Schultz, "Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart," Circulation Research, vol. 69, no. 6, pp. 1476-1486, 1991.
24. M. Mitak, T. Gojmerac, B. Mandić, and Ž. Cvetnić, "Changes in serum concentration of 17β-estradiol in female rats during estrous cycle after treatment with atrazine and zearalenone," Veterinarni Medicina, vol. 46, no. 5, pp. 145-148, 2001.
25. B. Costa, S. Bendinelli, P. Gabelloni et al., "Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor," PLoS ONE, vol. 8, no. 8, Article ID e72281, 2013.
26. N. Höfer, P. Diel, J. Wittsiepe, M. Wilhelm, F. M. Kluxen, and G. H. Degen, "Investigations on the estrogenic activity of the metallohormone cadmium in the rat intestine," Archives of Toxicology, vol. 84, no. 7, pp. 541-552, 2010.
27. S. Daniele, S. Taliani, E. Da Pozzo et al., "Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in Glioblastoma," Scientific Reports, vol. 4, article 4749, 2014.
28. A. Barzegar and A. A. Moosavi-Movahedi, "Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin," PLoS ONE, vol. 6, no. 10, Article ID e26012, 2011.
29. N. P. Singh, M. T. McCoy, R. R. Tice, and E. L. Schneider, "A simple technique for quantitation of low levels of DNA damage in individual cells," Experimental Cell Research, vol. 175, no. 1, pp. 184-191, 1988.
30. L. Giovannelli, A. Cozzi, I. Guarnieri, P. Dolara, and F. Moroni, "Comet assay as a novel approach for studying DNA damage in focal cerebral ischemia: differential effects of NMDA receptor antagonists and poly(ADP-ribose) polymerase inhibitors," Journal of Cerebral Blood Flow and Metabolism, vol. 22, no. 6, pp. 697-704, 2002.
31. E. da Pozzo, C. Giacomelli, B. Costa et al., "TSPO PIGA ligands promote neurosteroidogenesis and human astrocyte well-being," International Journal of Molecular Sciences, vol. 17, no. 7, article 1028, 2016.
32. D. D. Dunigan, S. B. Waters, and T. C. Owen, "Aqueous soluble tetrazolium/formazan MTS as an indicator of NADH-and NADPH-dependent dehydrogenase activity," BioTechniques, vol. 19, no. 4, pp. 640-649, 1995.
33. B. Costa, E. Da Pozzo, C. Giacomelli et al., "TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance," Apoptosis, vol. 20, no. 3, pp. 383-398, 2015.
34. J. Mulero, J. Bernabé, B. Cerdá et al., "Variations on cardiovascular risk factors inmetabolic syndrome after consume of a citrusbased juice," Clinical Nutrition, vol. 31, no. 3, pp. 372-377, 2012.
35. S. Buscemi, G. Rosafio, G. Arcoleo et al., "Effects of red orange juice intake on endothelial function and inflammatory markers in adult subjects with increased cardiovascular risk," American Journal of Clinical Nutrition, vol. 95, no. 5, pp. 1089-1095, 2012.
36. S. Kawaii, Y. Tomono, E. Katase, K. Ogawa, and M. Yano, "Quantitation of flavonoid constituents in Citrus fruits," Journal of Agricultural and Food Chemistry, vol. 47, no. 9, pp. 3565-3571, 1999.
37. I. Erlund, E. Meririnne, G. Alfthan, and A. Aro, "Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice," Journal of Nutrition, vol. 131, no. 2, pp. 235-241, 2001.
38. R. Bugianesi, G. Catasta, P. Spigno, A. D'Uva, and G. Maiani, "Naringenin from cooked tomato paste is bioavailable in men," Journal of Nutrition, vol. 132, no. 11, pp. 3349-3352, 2002.
39. G. M. Brett, W. Hollands, P. W. Needs et al., "Absorption, metabolism and excretion of flavanones fromsingle portions of orange fruit and juice and effects of anthropometric variables and contraceptive pill use on flavanone excretion," British Journal of Nutrition, vol. 101, no. 5, pp. 664-675, 2009.
40. J. S. Choi, K. Y. Park, S. H. Moon, S. H. Rhee, and H. S. Young, "Antimutagenic effect of plant flavonoids in the Salmonella assay system," Archives of Pharmacal Research, vol. 17, no. 2, pp. 71-75, 1994.
41. C.-H. Lee, T.-S. Jeong, Y.-K. Choi et al., "Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits," Biochemical and Biophysical Research Communications, vol. 284, no. 3, pp. 681-688, 2001.
42. I. A. Ribeiro, J. Rocha, B. Sepodes, H. Mota-Filipe, and M. H. Ribeiro, "Effect of naringin enzymatic hydrolysis towards naringenin on the anti-inflammatory activity of both compounds," Journal of Molecular Catalysis B: Enzymatic, vol. 52-53, no. 1-4, pp. 13-18, 2008.
43. J. Renugadevi and S. M. Prabu, "Cadmium-induced hepatotoxicity in rats and the protective effect of naringenin," Experimental and Toxicologic Pathology, vol. 62, no. 2, pp. 171-181, 2010.
44. B.-D. Wang, Z.-Y. Yang, Q. Wang, T.-K. Cai, and P. Crewdson, "Synthesis, characterization, cytotoxic activities, and DNAbinding properties of the La(III) complex with Naringenin Schiff-base," Bioorganic and Medicinal Chemistry, vol. 14, no. 6, pp. 1880-1888, 2006.
45. A. V. Kuznetsov, S. Javadov, S. Sickinger, S. Frotschnig, and M. Grimm, "H9c2 and HL-1 cells demonstrate distinct features of energy metabolism, mitochondrial function and sensitivity to hypoxia-reoxygenation," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1853, no. 2, pp. 276-284, 2015.
46. R. M. Crawford, S. Jovanović, G. R. Budas et al., "Chronic mild hypoxia protects heart-derived H9c2 cells against acute hypoxia/reoxygenation by regulating expression of the SUR2A subunit of the ATP-sensitive K+ channel," Journal of Biological Chemistry, vol. 278, no. 33, pp. 31444-31455, 2003.
47. S. Jovanović, Q. Du, A. Sukhodub, and A. Jovanović, "A dual mechanism of cytoprotection afforded by M-LDH in embryonic heart H9C2 cells," Biochimica et Biophysica Acta (BBA)- Molecular Cell Research, vol. 1793, no. 8, pp. 1379-1386, 2009.
48. S. Jovanović, Q. Du, A. Sukhodub, and A. Jovanović, "MLDH physically associated with sarcolemmal K ATP channels mediates cytoprotection in heart embryonic H9C2 cells," The International Journal of Biochemistry & Cell Biology, vol. 41, no. 11, pp. 2295-2301, 2009.
49. Y. Zhang, D. Wang, K. Cao, M. Chen, X. Yang, and Y. Tao, "Rat induced pluripotent stem cells protect H9C2 cells from cellular senescence via a paracrine mechanism," Cardiology (Switzerland), vol. 128, no. 1, pp. 43-50, 2014.
50. B. B. de Jesus and M. A. Blasco, "Assessing cell and organ senescence biomarkers," Circulation research, vol. 111, no. 1, pp. 97-109, 2012.
51. T. Kuilman, C. Michaloglou, W. J. Mooi, and D. S. Peeper, "The essence of senescence," Genes and Development, vol. 24, no. 22, pp. 2463-2479, 2010.
52. V. Gire and V. Dulic, "Senescence from G2 arrest, revisited," Cell Cycle, vol. 14, no. 3, pp. 297-304, 2015.
53. K. Oyama, K. Takahashi, and K. Sakurai, "Hydrogen peroxide induces cell cycle arrest in cardiomyoblast H9c2 cells, which is related to hypertrophy," Biological and Pharmaceutical Bulletin, vol. 34, no. 4, pp. 501-506, 2011.
54. R. Lüpertz, W. Wätjen, R. Kahl, and Y. Chovolou, "Doseand time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells," Toxicology, vol. 271, no. 3, pp. 115-121, 2010.
55. F. I. Kanaze, M. I. Bounartzi, M. Georgarakis, and I. Niopas, "Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects," European Journal of Clinical Nutrition, vol. 61, no. 4, pp. 472-477, 2007.
56. C. Shen, J. Jiang, L. Yang, D. Wang, and W. Zhu, "Antiageing active ingredients from herbs and nutraceuticals used in traditional Chinese medicine: pharmacological mechanisms and implications for drug discovery," British Journal of Pharmacology, 2016.
57. K. Zygmunt, B. Faubert, J. MacNeil, and E. Tsiani, "Naringenin, a citrus flavonoid, increases muscle cell glucose uptake via AMPK," Biochemical and Biophysical Research Communications, vol. 398, no. 2, pp. 178-183, 2010.
58. D.-F. Dai and P. S. Rabinovitch, "Cardiac aging in mice and humans: the role of mitochondrial oxidative stress," Trends in Cardiovascular Medicine, vol. 19, no. 7, pp. 213-220, 2009.
59. J. Wu, S. Xia, B. Kalionis, W. Wan, and T. Sun, "The role of oxidative stress and inflammation in cardiovascular aging," BioMed Research International, vol. 2014, Article ID 615312, 13 pages, 2014.
60. R. M. Martinez, F. A. Pinho-Ribeiro, V. S. Steffen et al., "Naringenin inhibits UVB irradiation-induced inflammation and oxidative stress in the skin of hairless mice," Journal of Natural Products, vol. 78, no. 7, pp. 1647-1655, 2015.
61. D. V. Ziegler, C. D. Wiley, and M. C. Velarde, "Mitochondrial effectors of cellular senescence: beyond the free radical theory of aging," Aging Cell, vol. 14, no. 1, pp. 1-7, 2015.
62. C. D. Wiley, M. C. Velarde, P. Lecot et al., "Mitochondrial dysfunction induces senescence with a distinct secretory phenotype," Cell Metabolism, vol. 23, no. 2, pp. 303-314, 2016.
63. S. Gallage and J. Gil, "Mitochondrial dysfunction meets senescence," Trends in Biochemical Sciences, vol. 41, no. 3, pp. 207-209, 2016.
64. D.-F. Dai, P. S. Rabinovitch, and Z. Ungvari, "Mitochondria and cardiovascular aging," Circulation Research, vol. 110, no. 8, pp. 1109-1124, 2012.
65. L. Argaud, O. Gateau-Roesch, L. Augeul et al., "Increased mitochondrial calcium coexists with decreased reperfusion injury in postconditioned (but not preconditioned) hearts," American Journal of Physiology-Heart and Circulatory Physiology, vol. 294, no. 1, pp. H386-H391, 2008.
66. M. Picard, K. J. Wright, D. Ritchie, M. M. Thomas, and R. T. Hepple, "Mitochondrial function in permeabilized cardiomyocytes is largely preserved in the senescent rat myocardium," PLoS ONE, vol. 7, no. 8, Article ID e43003, 2012.
67. M. A. Aon, S. Cortassa, A.-C. Wei, M. Grunnet, and B. O'Rourke, "Energetic performance is improved by specific activation of K+ fluxes through KCa channels in heart mitochondria," Biochimica et Biophysica Acta, vol. 1797, no. 1, pp. 71-80, 2010.
68. J. R. Speakman, D. A. Talbot, C. Selman et al., "Uncoupled and surviving: individual mice with high metabolism have greater mitochondrial uncoupling and live longer," Aging Cell, vol. 3, no. 3, pp. 87-95, 2004.
69. E. Murphy, "Estrogen signaling and cardiovascular disease," Circulation Research, vol. 109, no. 6, pp. 687-696, 2011.
70. M. E. Mendelsohn and R. H. Karas, "The protective effects of estrogen on the cardiovascular system," New England Journal of Medicine, vol. 340, no. 23, pp. 1801-1811, 1999.
71. T. Luo and J. K. Kim, "The role of estrogen and estrogen receptors on cardiomyocytes: an overview," Canadian Journal of Cardiology, vol. 32, no. 8, pp. 1017-1025, 2016.
72. C. Grohé, S. Kahlert, K. Löbbert, and H. Vetter, "Expression of oestrogen receptor α and β in rat heart: role of local oestrogen synthesis," Journal of Endocrinology, vol. 156, no. 2, pp. R1-R7, 1998.
73. R. S. Rosenberg Zand, D. J. A. Jenkins, and E. P. Diamandis, "Steroid hormone activity of flavonoids and related compounds," Breast Cancer Research and Treatment, vol. 62, no. 1, pp. 35-49, 2000.
74. O. Zierau, J. Hamann, S. Tischer et al., "Naringenin-type flavonoids show different estrogenic effects in mammalian and teleost test systems," Biochemical and Biophysical Research Communications, vol. 326, no. 4, pp. 909-916, 2005.